The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Open accessAbstract
The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Control of mammary stem cell function by steroid hormone signalling
Asselin-Labat, M.-L., Vaillant, F., Sheridan, J. M., Pal, B., Wu, D., Simpson, E. R., Yasuda, H., Smyth, G. K., Martin, T. J., Lindeman, G. J., et al. (2010) · Nature · doi:10.1038/nature09027 · Cited by 693 · cited 1×
“This is thought to be mediated through paracrine signaling involving RANK ligand [54].”
Background
Cited by
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Metastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment
Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018) · Radiology · doi:10.1148/radiol.2018172171 · Cited by 275
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Metabolic reprogramming in triple-negative breast cancer
Wang, Z., Jiang, Q., & Dong, C. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0210 · Cited by 248
Castelló, A., Pollán, M., Buijsse, B., Ruiz, A., Casas, A. M., Baena-Cañada, J. M., Lope, V, Antolín, S., Ramos, M., Muñoz, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.434 · Cited by 182
Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer
Samuel, S. M., Varghese, E., Varghese, S., & Büsselberg, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.004 · Cited by 141
Liu, T., Huang, J., Liao, T., Pu, R., Liu, S., & Peng, Y. (2022) · IRBM · doi:10.1016/j.irbm.2020.12.002 · Cited by 137
Kim, J.-Y., Jeong, H. S., Chung, T., Kim, M., Lee, J. H., Jung, W. H., & Koo, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17775 · Cited by 115
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
Huang, Y., Wei, L., Hu, Y., Shao, N., Lin, Y., He, S., Shi, H., Zhang, X., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706733 · Cited by 82
Neven, P., Markopoulos, C., Tanner, M., Marty, M., Kreienberg, R., Atkins, L., Franquet, A., Gnant, M., Neciosup, S., Tesarova, P., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.009 · Cited by 53
Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., et al. (2016) · Surgery Today · doi:10.1007/s00595-015-1252-x · Cited by 45
Rondón-Lagos, M., Verdun Di Cantogno, L., Marchiò, C., Rangel, N., Payan-Gomez, C., Gugliotta, P., Botta, C., Bussolati, G., Ramírez-Clavijo, S. R., Pasini, B., et al. (2014) · Molecular Cytogenetics · doi:10.1186/1755-8166-7-8 · Cited by 43
Ayoub, N., Al-Shami, K., Alqudah, M. A. Y., & Mhaidat, N. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s148604 · Cited by 38
A high-fat diet increases the incidence of mammary cancer inc-Ha-ras proto-oncogene transgenic rats
Magaki, M., Ishii, H., Yamasaki, A., Kitai, Y., Kametani, S., Nakai, R., Dabid, A., Tsuda, H., & Ohnishi, T. (2017) · Journal of Toxicologic Pathology · doi:10.1293/tox.2016-0052 · Cited by 10
Hashimoto Takigami, N., Kuniyoshi, S., Miki, Y., Tamaki, K., Kamada, Y., Uehara, K., Tsuchiya, S., Terukina, S., Iwabuchi, E., Kanai, A., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06288-3 · Cited by 10
Metadata
- Authors
- Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 22
- Issue
- 8
- Pages
- 1736-1747
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2132893003
- Cited by
- 3,836
- References
- 3
- FWCI
- 93.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
